Volume 21, Issue 6 (November-December 2022)
Payesh 2022, 21(6): 581-592 |
Back to browse issues page
Ethics code: 11/104276
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sasanipour M, Khosravi A. Increase in life expectancy due to changes in the patterns of deaths from cardiovascular diseases in Iran during 2006-2019. Payesh 2022; 21 (6) :581-592
URL: http://payeshjournal.ir/article-1-1912-en.html
URL: http://payeshjournal.ir/article-1-1912-en.html
1- Center for Health Network Management, Deputy for Public Health, Ministry of Health and Medical Education, Tehran, Iran
2- National Institute for Population Research, Tehran, Iran
2- National Institute for Population Research, Tehran, Iran
Abstract: (841 Views)
Objective(s): Since cardiovascular diseases have been the dominant cause of death in Iran in recent decades, on this basis, this study amid to determine the role of changes in the epidemiological pattern of this cause of death in increasing the life expectancy of Iranians in both sexes from 2006 to 2019.
Methods: Information on the cause of death by age and sex for the years 2006 and 2019 was obtained from the death registration system of the Ministry of Health and Medical Education. Using the standard life table technique, life expectancies at birth were calculated for the years 2006 and 2019. Then the role of decrease in deaths due to cardiovascular diseases in improving life expectancy was analyzed by sex.
Results: From 2006 to 2019, about 3.8 years have been added to the life expectancy of females and 4.5 years to the life expectancy of Iranian males. The decrease in the death rate due to heart attack has led to the improvement of the life expectancy of women and men, by 1.5 years and 1.4 years, respectively. Also, 0.8 years and 0.6 years of increase in life expectancy of women and men in Iran were due to changes in deaths from stroke. In addition, the impact of various types of cardiovascular diseases on increasing life expectancy has been caused by changes in the pattern of death in old age.
Conclusion: The increase in life expectancy in Iran has been achieved mainly through changes in old-age mortality, especially due to cardiovascular diseases. Due to age structure transitions, this trend is expected to continue in the future, which has important implications for health care planning and future prevention strategies.
Methods: Information on the cause of death by age and sex for the years 2006 and 2019 was obtained from the death registration system of the Ministry of Health and Medical Education. Using the standard life table technique, life expectancies at birth were calculated for the years 2006 and 2019. Then the role of decrease in deaths due to cardiovascular diseases in improving life expectancy was analyzed by sex.
Results: From 2006 to 2019, about 3.8 years have been added to the life expectancy of females and 4.5 years to the life expectancy of Iranian males. The decrease in the death rate due to heart attack has led to the improvement of the life expectancy of women and men, by 1.5 years and 1.4 years, respectively. Also, 0.8 years and 0.6 years of increase in life expectancy of women and men in Iran were due to changes in deaths from stroke. In addition, the impact of various types of cardiovascular diseases on increasing life expectancy has been caused by changes in the pattern of death in old age.
Conclusion: The increase in life expectancy in Iran has been achieved mainly through changes in old-age mortality, especially due to cardiovascular diseases. Due to age structure transitions, this trend is expected to continue in the future, which has important implications for health care planning and future prevention strategies.
type of study: Descriptive |
Subject:
Public Health
Received: 2022/07/4 | Accepted: 2022/12/24 | ePublished ahead of print: 2023/01/2 | Published: 2023/01/2
Received: 2022/07/4 | Accepted: 2022/12/24 | ePublished ahead of print: 2023/01/2 | Published: 2023/01/2
References
1. United Nations. World Mortality Report 2015 Highlights. Department of Economic and Social Affairs. 1st Edition, Population Division: New York, 2017
2. Santosa A, Wall S, Fottrell E, Högberg U, Byass P. The development and experience of epidemiological transition theory over four decades: a systematic review. Global Health Action 2014;7:235-74 [DOI:10.3402/gha.v7.23574]
3. McKeown R. The epidemiologic transition: changing patterns of mortality and population dynamics. American Journal of Lifestyle Medicine 2009;3:19-26 [DOI:10.1177/1559827609335350]
4. Mc Namara K, Alzubaidi H, Jackson JK. Cardiovascular disease as a leading cause of death: how are pharmacists getting involved? Integrated Pharmacy Research & Practice 2019;8:1-15 [DOI:10.2147/IPRP.S133088]
5. Mensah GA, Roth GA, Fuster V. The global burden of cardiovascular diseases and risk factors: 2020 and beyond. Journal of the American College of Cardiology 2019;74:2529-32 [DOI:10.1016/j.jacc.2019.10.009]
6. Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. International Journal of Cardiology 2013;168:934-45 [DOI:10.1016/j.ijcard.2012.10.046]
7. Baptista EA, Queiroz BL. The relation between cardiovascular mortality and development. Demographic Research 2019;41:1437-52 [DOI:10.4054/DemRes.2019.41.51]
8. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. Journal of the American College of Cardiology. 2020;76:2982-3021 [DOI:10.1016/j.jacc.2020.11.010]
9. Franco M, Cooper RS, Bilal U, Fuster V. Challenges and opportunities for cardiovascular disease prevention. The American Journal of Medicine 2011; 124: 95-102 [DOI:10.1016/j.amjmed.2010.08.015]
10. Lopez A.D, Adair T. Is the long-term decline in cardiovascular-disease mortality in high-income countries over? Evidence from national vital statistics. International Journal of Epidemiology 2019;48:1815-1823 [DOI:10.1093/ije/dyz143]
11. Baptista E.A, Queiroz B. Spatial analysis of mortality by cardiovascular disease in the adult population: a study for Brazilian micro-regions between 1996 and 2015. Spatial Demography 2019; 7: 83-101 [DOI:10.1007/s40980-019-00050-6]
12. Bambra C, Joyce K. E, Maryon-Davies A. Strategic review of health inequalities in England post-2010 (Marmot Review): Task Group 8 : priority public health conditions : final report.', Project Report. University College London, Department of Epidemiology and Public Health, the Global Health Equity Group, London. 2010. https://dro.dur.ac.uk/6396/
13. Vallin J, Meslé F. Convergences and divergences in mortality. A new approach to health transition. Demographic Research Special Collection 2004;2: 11-44 [DOI:10.4054/DemRes.2004.S2.2]
14. Sasanipour M, Mohebbi Meymandi M. Investigating the possibility of improving life expectancy in Iran by eliminating the main causes of death during the period 2006-2015. Bi-Quarterly Journal of Demographic Studies 2019;5:7-29 [in Persian]
15. Sasanipour M, Koosheshi M, Askari-Nodoushan A, Khosravi A. The role of age and causes of death changes in increasing life expectancy in Iran during last decade. Journal of Population Association of Iran 2018;12:109-134 [in Persian]
16. Mirzaei M. Population and Development with Emphasis on Iran (Ten Articles). 1st Edition, Asia-Pacific Population Studies: Tehran, 2005
17. Sepanlou SG, Parsaeian M, Krohn KJ, Afshin A, Farzadfar F, Roshandel G, et al. Disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE) in Iran and its neighboring countries, 1990-2015: Findings from global burden of disease study 2015. Archive of Iranian Medicine 2017; 20: 403-418
18. Khosravi A, Taylor R, Naghavi M, Lopez AD. Mortality in the Islamic Republic of Iran, 1964-2004. Bulletin of the World Health Organization 2007; 85: 607-614 [DOI:10.2471/BLT.06.038802]
19. United Nations Inter-agency Group for Child Mortality Estimation. UN IGME Total Under-5 Mortality Rate, Infant Mortality Rate and Neonatal Mortality Rate database 2020. https://childmortality.org/. 12 December 2021. 20.
20. Moultrie TA, Dorrington R, Hill A, Hill K, Timaeus T, Zaba B. Tools for demographic estimation. 1st Edition, International :union: for the Scientific Study of Population: Paris, 2013
21. Vaupel W, Romo C. Decomposing change in life expectancy: A bouquet of formulas in honor of Nathan Keyfitz's 90th birthday. Demography 2003;40:201-16 [DOI:10.1353/dem.2003.0018]
22. Arriaga EE. Measuring and explaining the change in life expectancies. Demography 1984;21:83-96 [DOI:10.2307/2061029]
23. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269-76 [DOI:10.1016/S0140-6736(96)07493-4]
24. Bonneux LG, Huisman CC, de Beer JA. Mortality in 272 European regions, 2002-2004. An update. European Journal of Epidemiology 2010;25:77-85 [DOI:10.1007/s10654-009-9415-y]
25. Helis E, Augustincic L, Steiner S, Chen L, Turton P, Fodor JG. Time trends in cardiovascular and all-cause mortality in the "old" and "new" European :union: countries. European Journal of Cardiovascular Prevention and Rehabilitation 2011;18:347-59 [DOI:10.1177/1741826710389361]
26. Wilmot KA, O'Flaherty M, Capewell S, Ford ES, Vaccarino V. Coronary heart disease mortality declines in the United States from 1979 through 2011: evidence for stagnation in young adults, especially women. Circulation 2015;132:997-1002 [DOI:10.1161/CIRCULATIONAHA.115.015293]
27. O'Flaherty M, Ford E, Allender S, Scarborough P, Capewell S. Coronary heart disease trends in England and Wales from 1984 to 2004: concealed levelling of mortality rates among young adults. Heart 2008; 94:178-181 [DOI:10.1136/hrt.2007.118323]
28. Vaartjes I, O'Flaherty M, Grobbee DE, Bots ML, Capewell S. Coronary heart disease mortality trends in the Netherlands 1972-2007. Heart 2011;97:569-573 [DOI:10.1136/hrt.2010.206565]
29. Institute for Health Metrics and Evaluation. GBD Compare. Sattle, AA: IHME,University of Washington, 2021Olshansky S, Ault B. The fourth stage of the epidemiologic transition: The age of delayed degenerative diseases. The Milbank Quarterly 1986; 64: 355-391 [DOI:10.2307/3350025]
30. Santosa A, Wall S, Fottrell E, Högberg U, Byass P. The development and experience of epidemiological transition theory over four decades: a systematic review. Global health Action 2014; 7: 1-16 [DOI:10.3402/gha.v7.23574]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |